The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

  1. First select the CSR Section, then a Table/Figure from that section.
  2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 528 KB) and Technical Notes (PDF, 794 KB) pages.


Download and Print: Download Printer-friendly PDF Download data


Table 4.26

Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
Females by Race

Histologya All Races White Black Asian/
Pacific Islander
American Indian
/Alaska Nativeb
Hispanicc
Count Percent Count Percent Count Percent Count Percent Count Percent Count Percent
Adenocarcinomad 111,997 99.9% 85,458 99.9% 13,652 99.9% 10,843 99.9% 345 99.7% 12,322 99.9%
Adenocarcinoma in situ, NOS (8140/2) - - - - - - - - - - - -
Ductal carcinoma in situ e 91,147 81.3% 68,476 80.1% 11,616 85.0% 9,542 87.9% 306 88.4% 10,110 81.9%
Cribiform carcinoma in situ (8201/2) 9,938 8.9% 7,393 8.6% 1,262 9.2% 1,111 10.2% 25 7.2% 1,076 8.7%
Ductal carcinoma in situ, solid type(8230/2) 8,013 7.1% 6,193 7.2% 870 6.4% 832 7.7% 27 7.8% 766 6.2%
Ductal carcinoma in situ, NOS (8500/2) 25,679 22.9% 19,643 23.0% 3,129 22.9% 2,396 22.1% 108 31.2% 2,820 22.9%
Comedocarcinoma in situ (8501/2) 8,359 7.5% 6,352 7.4% 954 7.0% 931 8.6% 32 9.2% 910 7.4%
Ductal carcinoma in situ papillary(8503/2) 1,563 1.4% 1,034 1.2% 323 2.4% 171 1.6% - - 204 1.7%
Noninfiltrating intracystic carcinoma(8504/2) 317 0.3% 210 0.2% 51 0.4% 52 0.5% - - 36 0.3%
Ductal carcinoma in situ micropapillary(8507/2) 1,555 1.4% 1,187 1.4% 221 1.6% 125 1.2% - - 167 1.4%
Intraductal with other types of carcinoma in situ(8523/2) 35,468 31.6% 26,282 30.7% 4,786 35.0% 3,875 35.7% 106 30.6% 4,105 33.3%
Lobular carcinoma in situ (8520/2-8521/2, 8524/2) 16,547 14.8% 13,567 15.9% 1,538 11.3% 970 8.9% 34 9.8% 1,777 14.4%
Lobular carcinoma in situ, NOS (8520/2) 16,531 14.7% 13,558 15.9% 1,533 11.2% 969 8.9% 33 9.5% 1,775 14.4%
Lobular CISf with other CISf (8524/2) 16 0.0% - - - - - - - - - -
Intraductal and lobular in situ carcinoma (8522/2) 3,633 3.2% 2,929 3.4% 408 3.0% 250 2.3% - - 353 2.9%
Other adenocarcinomasg 661 0.6% 480 0.6% 89 0.7% 79 0.7% - - 82 0.7%
Other in situ histologiesh 115 0.1% 80 0.1% - - - - - - 16 0.1%
Total 112,112 100.0% 85,538 100.0% 13,667 100.0% 10,854 100.0% 346 100.0% 12,338 100.0%

Footnotes:

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts). Percents may not sum to 100 due to rounding.

a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

d Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

e Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

f CIS = Carcinoma in situ.

g Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

h Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.

Page Navigation: << Previous Next >>


The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.